Inactive Instrument

News Tenax Therapeutics Inc Nasdaq

Equities

US88032L1008

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Tenax Therapeutics: Q1 Earnings Snapshot	14/05	AQ
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	14/05	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	30/04	AQ
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	09/04	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	28/03	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Tenax Therapeutics to Present at the 36th Annual Roth Conference	12/03	AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	29/02	AQ
Tenax Therapeutics Secures Global Rights for Levosimendan	21/02	MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	20/02	CI
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	20/02	AQ
Top Midday Decliners	09/02	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	08/02	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	08/02	MT
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	08/02	AQ
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	08/02	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	08/02	AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	08/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tenax Therapeutics Inc Nasdaq

Equities

US88032L1008

Summary

Filters